The pharmacologic erection

R. W. Lewis

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Intracavernous pharmacologic agent injection has become a very important step in the evaluation of male erectile dysfunction, either alone or in association with other studies, such as a duplex Doppler evaluation, pharmacocavernosometry/pharmacocavernosography, or pharmacoarteriography. In addition, a large percentage of men with impotence may benefit from intracavernous injection therapy as one of their options for goal-directed treatment. With careful office testing to obtain an optimal minimal dose necessary to produce an erection lasting 30 minutes to 1 hour, and by teaching patients proper injection technique, including variance of injection site, significant side effects and the chance of priapism are minimal. Despite the lag of Food and Drug Administration approval, a wealth of literature, many in peer-reviewed literature, attest to the safety and efficacy of the use of intracavernous agents as both a diagnostic aid and a therapeutic tool.

Original languageEnglish (US)
Pages (from-to)541-558
Number of pages18
JournalProblems in Urology
Volume5
Issue number4
StatePublished - Jan 1 1991

Fingerprint

Injections
Erectile Dysfunction
Priapism
Drug Approval
United States Food and Drug Administration
Teaching
Therapeutics
Safety

ASJC Scopus subject areas

  • Urology

Cite this

Lewis, R. W. (1991). The pharmacologic erection. Problems in Urology, 5(4), 541-558.

The pharmacologic erection. / Lewis, R. W.

In: Problems in Urology, Vol. 5, No. 4, 01.01.1991, p. 541-558.

Research output: Contribution to journalArticle

Lewis, RW 1991, 'The pharmacologic erection', Problems in Urology, vol. 5, no. 4, pp. 541-558.
Lewis RW. The pharmacologic erection. Problems in Urology. 1991 Jan 1;5(4):541-558.
Lewis, R. W. / The pharmacologic erection. In: Problems in Urology. 1991 ; Vol. 5, No. 4. pp. 541-558.
@article{2a132964d1f74011a3713cdecf827bc2,
title = "The pharmacologic erection",
abstract = "Intracavernous pharmacologic agent injection has become a very important step in the evaluation of male erectile dysfunction, either alone or in association with other studies, such as a duplex Doppler evaluation, pharmacocavernosometry/pharmacocavernosography, or pharmacoarteriography. In addition, a large percentage of men with impotence may benefit from intracavernous injection therapy as one of their options for goal-directed treatment. With careful office testing to obtain an optimal minimal dose necessary to produce an erection lasting 30 minutes to 1 hour, and by teaching patients proper injection technique, including variance of injection site, significant side effects and the chance of priapism are minimal. Despite the lag of Food and Drug Administration approval, a wealth of literature, many in peer-reviewed literature, attest to the safety and efficacy of the use of intracavernous agents as both a diagnostic aid and a therapeutic tool.",
author = "Lewis, {R. W.}",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "5",
pages = "541--558",
journal = "Problems in Urology",
issn = "0889-471X",
number = "4",

}

TY - JOUR

T1 - The pharmacologic erection

AU - Lewis, R. W.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Intracavernous pharmacologic agent injection has become a very important step in the evaluation of male erectile dysfunction, either alone or in association with other studies, such as a duplex Doppler evaluation, pharmacocavernosometry/pharmacocavernosography, or pharmacoarteriography. In addition, a large percentage of men with impotence may benefit from intracavernous injection therapy as one of their options for goal-directed treatment. With careful office testing to obtain an optimal minimal dose necessary to produce an erection lasting 30 minutes to 1 hour, and by teaching patients proper injection technique, including variance of injection site, significant side effects and the chance of priapism are minimal. Despite the lag of Food and Drug Administration approval, a wealth of literature, many in peer-reviewed literature, attest to the safety and efficacy of the use of intracavernous agents as both a diagnostic aid and a therapeutic tool.

AB - Intracavernous pharmacologic agent injection has become a very important step in the evaluation of male erectile dysfunction, either alone or in association with other studies, such as a duplex Doppler evaluation, pharmacocavernosometry/pharmacocavernosography, or pharmacoarteriography. In addition, a large percentage of men with impotence may benefit from intracavernous injection therapy as one of their options for goal-directed treatment. With careful office testing to obtain an optimal minimal dose necessary to produce an erection lasting 30 minutes to 1 hour, and by teaching patients proper injection technique, including variance of injection site, significant side effects and the chance of priapism are minimal. Despite the lag of Food and Drug Administration approval, a wealth of literature, many in peer-reviewed literature, attest to the safety and efficacy of the use of intracavernous agents as both a diagnostic aid and a therapeutic tool.

UR - http://www.scopus.com/inward/record.url?scp=0026090958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026090958&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0026090958

VL - 5

SP - 541

EP - 558

JO - Problems in Urology

JF - Problems in Urology

SN - 0889-471X

IS - 4

ER -